Experimental hepatitis B drug bepirovirsen shows functional cure in some patients.
An experimental drug called bepirovirsen, developed by GSK and Ionis Pharmaceuticals, achieved functional cure in approximately 20% of patients across two international studies. The findings were published in the New England Journal of Medicine and presented at a scientific meeting in Barcelona.
0
Divergence score
2 outlets covered it, splitting into 1 framing camp across 1 bias group.
1 camp
1 bias group
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
PBS NewsHour
AP News
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Both outlets published identical AP wire copy with only minor headline variations, presenting the same findings, quotes, and context.
How each outlet covered it
No left-right split here
Coverage clusters in the center and international press. Here is each take as it stands.
Center & international coverage
“Hepatitis B drug may offer 'functional cure' for some patients”
“Experimental hepatitis B drug may offer 'functional cure' for some patients”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed